RE:Other Indications Impressive Preclinical Dataenriquesuave wrote: Colorectal preclinical subcutaneous mouse model Rutherin + X-Rays Vs X-Rays alone.
Tumor volume after 45 days
Rutherin : 30mm cube. Vs 330mm cube. Thus 90% improvement vs radiation alone
Rutherin survival at 70 days 63% vs 23% for radiation alone
Excellent improvement for GBM and NSCLC as well. It's in the MD&A on Sedar.
Enough cash for another 12 months as per report. Hopefully good data and SP increase before and/or BTD.
In the MD&A, TLT mentions the use of radiotherapy (RT), but they don't specify the type of RT they plan to use in their future GBM & NSCLC studies. I'm assuming external/x-ray. However, all of the following RT options are available: 1) only external 2) only internal/intraoperative RT or 3) a combination of the two.
Based on the various models/graphs depicted in the MD&A, it appears a less durable response was achieved using RT + Rutherrin in an "orthotopic" model vs the subcutaneous & in vitro models, which makes sense if you assume the tumor cells in the orthotopic model are deeper or less accessible to the RT/x-ray beam. It would obviously be a game changer if they are able to figure out a way to get similar results in humans using only external beam radiation...& the more targeted, less toxic & simpler, the better. My guess is a standard x-ray(s) wouldn't be enough. Hope I'm wrong. All imo.